Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Glofitamab and Gemcitabine and Oxaliplatin (Glofit-GemOx) Bridging to Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas

NCT07711483 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07711483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07711483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Glofitamab and Gemcitabine and Oxaliplatin (Glofit-GemOx) Bridging to Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 14, 2026
Completion date
October 1, 2030
Enrollment
56 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphomas, large b-cell lymphoma, lymphoma, relapsed/refractory large b-cell lymphoma